HCAC reviews applications pertaining to pathogen coinfections with HIV, and opportunistic infections due to HIV-associated compromise of the immune system. HCAC will review applications with a focus on AIDS-defining cancers, in the context of HIV coinfection and/or AIDS. HCAC will also review applications on non-AIDS-defining cancers in people living with chronic HIV infection and/or combination antiretroviral drug therapies (cART). Applications can address all aspects of molecular, animal model and clinical studies.
The membership panel is a list of chartered members only.
- Molecular, cellular, and immunological studies of the pathogenesis of AIDS-associated opportunistic pathogens (including viral, fungal, parasitic and bacterial pathogens), in the context of HIV coinfection and/or AIDS.
- Studies of AIDS-associated opportunistic pathogens in immunocompromised situations that closely mimic those associated with HIV infection.
- Studies of AIDS-defining cancers (e.g., Kaposi, lymphoma and cervical) and their causative viruses (e.g., KSHV, EBV and HPV), in the context of HIV coinfection and/or AIDS.
- Studies of non-AIDS-defining cancers (e.g., liver, lung, oral) in people living with chronic HIV infection and/or cART.
- Immune regulated therapeutic strategies for AIDS-associated opportunistic pathogens and cancers, in the context of HIV coinfection and/or AIDS.
- Preclinical and clinical ramifications and development of therapeutic approaches for opportunistic infections and HIV-associated and non-associated malignancies, in the context of HIV coinfection and/or AIDS.
- Mechanisms predisposing the elderly and infants to HIV coinfections and HIV associated malignancies.
- HIV Comorbidities and Clinical Studies Study Section (HCCS): HCAC reviews clinical studies related to HIV/AIDS-associated opportunistic infections and/or cancer, and certain non-clinical studies of HIV-associated end-organ disease. Clinical studies focused on the effects of chronic HIV infection and/or antiretroviral drug therapy on end-organ diseases are reviewed in HCCS.
- HIV molecular virology, cell biology, and drug development Study Section (HVCD): HCAC reviews studies on pre-clinical and clinical development of therapeutics for opportunistic infectious diseases and AIDS-associated malignancies, in the context of HIV coinfection and/or AIDS. Pre-clinical development of antiretroviral drugs, drug delivery and drug resistance are reviewed in HVCD.
- HIV Immunopathogenesis and Vaccine Development Study Section (HIVD): HCAC reviews applications on immunopathogenesis associated with opportunistic infections, in the context of HIV coinfection and/or AIDS. Studies that address immune mechanisms and vaccines for HIV-associated opportunistic pathogens may be reviewed in HIVD.
- Population and Public Health Approaches to HIV/AIDS Study Section (PPAH): Studies of HIV coinfections and HIV associated cancers in human populations employing biological assays and/or focusing on biological outcomes are reviewed in HCAC. Studies of HIV coinfections and HIV associated cancers in human populations employing behavioral measures and/or behavioral outcomes may be reviewed in PPAH.
Only applications in which there is a clear and compelling HIV/AIDS research component in the proposed research plan are eligible for the AIDS deadlines and review in HCAC and other AARR study sections. Those deemed insufficiently related to HIV/AIDS are assigned to other study sections and must be submitted in time to meet the regular non-AIDS application due dates. Applicants might consider requesting study sections in the following integrated review groups (IRGs):
- Infectious Diseases and Microbiology (IDM); IDM reviews applications involving the basic biology of microbes (excluding HIV), multicellular parasites and their vectors, and the infections and diseases caused by these agents.
- Immunology (IMM); The IMM scope of science includes studies of the immune system’s role in host interactions with infectious microbes (excluding HIV) and tumor cells.
- Oncology 1 – Basic Translational (OBT); OBT reviews applications involving basic and translational investigations that encompass cancer initiation, promotion, progression, and metastasis.
- Oncology 2 – Translational Clinical (OTC). OTC reviews applications involving translational and clinical investigations that encompass cancer prevention, diagnosis and treatment.